Literature DB >> 16107227

Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury.

Kenneth L Brigham.   

Abstract

Entities:  

Year:  2005        PMID： 16107227     DOI： 10.1007/s11908-005-0004-2

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN： 1523-3847            Impact factor:   3.725


× No keyword cloud information.
  8 in total

Review 1.  Invited review: mechanisms of ventilator-induced lung injury: a perspective.

Authors:  C C Dos Santos; A S Slutsky
Journal:  J Appl Physiol (1985)       Date:  2000-10

2.  Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.

Authors:  Roy G Brower; Michael A Matthay; Alan Morris; David Schoenfeld; B Taylor Thompson; Arthur Wheeler
Journal:  N Engl J Med       Date:  2000-05-04       Impact factor: 91.245

3.  Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome.

Authors:  Yumiko Imai; Jean Parodo; Osamu Kajikawa; Marc de Perrot; Stefan Fischer; Vern Edwards; Ernest Cutz; Mingyao Liu; Shaf Keshavjee; Thomas R Martin; John C Marshall; V Marco Ranieri; Arthur S Slutsky
Journal:  JAMA       Date:  2003 Apr 23-30       Impact factor: 56.272

4.  Injurious ventilatory strategies increase cytokines and c-fos m-RNA expression in an isolated rat lung model.

Authors:  L Tremblay; F Valenza; S P Ribeiro; J Li; A S Slutsky
Journal:  J Clin Invest       Date:  1997-03-01       Impact factor: 14.808

5.  Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: a randomized controlled trial.

Authors:  V M Ranieri; P M Suter; C Tortorella; R De Tullio; J M Dayer; A Brienza; F Bruno; A S Slutsky
Journal:  JAMA       Date:  1999-07-07       Impact factor: 56.272

6.  Interleukin-8 in sepsis: relation to shock and inflammatory mediators.

Authors:  C E Hack; M Hart; R J van Schijndel; A J Eerenberg; J H Nuijens; L G Thijs; L A Aarden
Journal:  Infect Immun       Date:  1992-07       Impact factor: 3.441

7.  Statistical evaluation of ventilator-free days as an efficacy measure in clinical trials of treatments for acute respiratory distress syndrome.

Authors:  David A Schoenfeld; Gordon R Bernard
Journal:  Crit Care Med       Date:  2002-08       Impact factor: 7.598

8.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality.

Authors:  M R Pinsky; J L Vincent; J Deviere; M Alegre; R J Kahn; E Dupont
Journal:  Chest       Date:  1993-02       Impact factor: 9.410
  8 in total
  5 in total

1.  Protective Effects of Isoliquiritigenin on LPS-Induced Acute Lung Injury by Activating PPAR-γ.

Authors:  Wenbin Zhang; Gui Wang; Shujun Zhou
Journal:  Inflammation       Date:  2018-08       Impact factor: 4.092

2.  Inhibition of miR-221 alleviates LPS-induced acute lung injury via inactivation of SOCS1/NF-κB signaling pathway.

Authors:  Tao Wang; Lihua Jiang; Xiaoyong Wei; Zhenghua Dong; Bo Liu; Junbo Zhao; Lijuan Wang; Peilin Xie; Yuxia Wang; Shangyou Zhou
Journal:  Cell Cycle       Date:  2019-07-11       Impact factor: 4.534

3.  Sevoflurane alleviates LPS‑induced acute lung injury via the microRNA‑27a‑3p/TLR4/MyD88/NF‑κB signaling pathway.

Authors:  Yunfei Wang; Xiaoran Zhang; Jianmin Tian; Guoze Liu; Xiaofang Li; Dan Shen
Journal:  Int J Mol Med       Date:  2019-05-30       Impact factor: 4.101

4.  Rosiglitazone Reduces Apoptosis and Inflammation in Lipopolysaccharide-Induced Human Umbilical Vein Endothelial Cells.

Authors:  Xiao-Xia Ji; Xiao-Jing Ji; Qian-Qian Li; Xiao-Xian Lu; Liang Luo
Journal:  Med Sci Monit       Date:  2018-09-06

5.  Divergence between serum creatine and cystatin C in estimating glomerular filtration rate of critically ill COVID-19 patients.

Authors:  Yanan Liu; Peng Xia; Wei Cao; Zhengyin Liu; Jie Ma; Ke Zheng; Limeng Chen; Xuewang Li; Yan Qin; Xuemei Li
Journal:  Ren Fail       Date:  2021-12       Impact factor: 2.606
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.